|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 8/04/09 Proteonomix, Inc. 10-12G 31:1.5M Yes International/FA |
Document/Exhibit Description Pages Size 1: 10-12G Registration Statement HTML 532K 2: EX-2.1 Plan of Acquisition HTML 173K 3: EX-3.1 Articles of Incorporation HTML 13K 12: EX-3.10 By-Laws HTML 59K 4: EX-3.2 Articles of Incorporation HTML 12K 5: EX-3.3 Articles of Incorporation HTML 14K 6: EX-3.4 Articles of Incorporation HTML 12K 7: EX-3.5 Articles of Incorporation HTML 12K 8: EX-3.6 Articles of Incorporation HTML 12K 9: EX-3.7 Articles of Incorporation HTML 14K 10: EX-3.8 Articles of Incorporation HTML 13K 11: EX-3.9 Articles of Incorporation HTML 53K 13: EX-10.1 Material Contract HTML 44K 22: EX-10.10 Material Contract HTML 33K 23: EX-10.11 Material Contract HTML 48K 24: EX-10.12 Material Contract HTML 16K 25: EX-10.13 Material Contract HTML 21K 26: EX-10.14 Material Contract HTML 43K 27: EX-10.15 Material Contract HTML 27K 28: EX-10.16 Material Contract HTML 18K 29: EX-10.17 Material Contract HTML 47K 30: EX-10.18 Material Contract HTML 42K 31: EX-10.19 Material Contract HTML 30K 14: EX-10.2 Material Contract HTML 26K 15: EX-10.3 Material Contract HTML 27K 16: EX-10.4 Material Contract HTML 45K 17: EX-10.5 Material Contract HTML 29K 18: EX-10.6 Material Contract HTML 34K 19: EX-10.7 Material Contract HTML 14K 20: EX-10.8 Material Contract HTML 43K 21: EX-10.9 Material Contract HTML 28K
Exhibit 10.10
ASSIGNMENT OF TECHNOLOGIES AND PATENT APPLICATIONS
FROM MICHAEL COHEN AND JACOB COHEN TO PROTEONOMIX, INC.
This Assignment Agreement (the “Agreement”) is made this 1st day of July, 2009, by and among Michael Cohen, residing at 7 Stanford Court, West Orange, New Jersey 07052 (“MC”); Jacob Cohen, residing at 25 Brook Place West Orange, New Jersey 07052 (“JC”)(herein individually an “Assignor” and collectively the “Assignors”); Proteonomix, Inc., a Delaware corporation (“Proteonomix”) and its subsidiary, Proteoderm, Inc. a New York corporation (the “Subsidiary”), both with offices at 187 Mill Lane, Mountainside, New Jersey 07092 (together, the “Parties”), entered into this 1st day of July, 2009.
WHEREAS, the Assignors jointly own all rights, title and interest in and to certain technologies and have filed patent applications therefor with the U.S. Patent and Trademark Office on December 19, 2006, as follows: Patent Application Serial No. 60/875,558 (Umbilical Cord Stem Cell Secreted Product Derived Topical Compositions and Methods of Use Thereof), and Patent Application Serial No. 60/875,553 (Embryonic Germ Cell Secreted Product Derived Topical Compositions and Methods of Use Thereof) (herein, the “Patent Applications”); and
WHEREAS, the Patent Applications include any amendments and all continuations, continuations in part, divisions, reissues, reexaminations or extensions thereof, any corresponding foreign patent applications, and any patents or other equivalent foreign patent rights issued, granted or registered thereon, any and all improvements developed by MC or JC or any entity or person working in concert with or on behalf of the Assignor, whether patentable or not, relating to such patent rights, which Assignor may now have or may hereafter develop, own or control, and all technology, trade secrets and know-how related to such patent rights (the “Patent Rights”).
WHEREAS, the Assignors desire to assign all their rights, title and interest in and to the Patent Applications, to Proteonomix, and Proteonomix desires to accept such assignment on the terms and conditions set forth herein;
NOW, THEREFORE, in consideration of the promises, agreements and mutual covenants set forth herein, and other good and valuable consideration as set forth herein, the Parties agree as follows:
1. Effective Date of Assignment. The Assignors hereby irrevocably transfer all of their rights, title and interest in and to the Patent Applications to Proteonomix, as of the date first above written.
2. Consideration for the Assignment. As consideration (the “Consideration”) for the assignment of the Properties to Proteonomix, Proteonomix hereby grants to the Assignors:
a)
fifty thousand (50,000) shares of Proteonomix Series C Preferred Stock; and
b)
the right to receive twenty (20%) percent of the issued and outstanding common stock of Proteoderm, in the event Proteoderm shall become a public company such percentage calculated immediately prior to any public offering or merger consideration.
The Consideration is non-transferable except to the JSM Family Trust.
3. Warranties of the Assignors. The Assignors hereby represent and warrant to Proteonomix that: (a) they are the sole owners of the Patent Rights; (b) they have not granted, and will not grant, any licenses or assignments to any other person or entity; (c) each Assignor has the right and power to enter into this Agreement and to assign the Patent Applications as provided herein; and (d)neither Assignor is aware of any person or entity infringing on the Patent Rights or that the Patent Rights infringe upon any other patent. In the event that either Assignor should learn, after execution hereof, that any person or entity may be infringing upon the Patent Applications, the Assignors and/or each of them will immediately notify Proteonomix of such possible infringement.
4. Warranties of Proteonomix. Proteonomix hereby acknowledges that the Assignors make no representations as to (a) the operability or fitness for any use of the products covered by the Patent Applications or the patentability, and/or the breadth of the Patent Rights; (b) the safety and/or efficacy of the technologies covered by the Patent Applications; (c) the ability to obtain regulatory approval of the
Page 1 of 5
Patent Applications; (d) whether there are any patents now held, or which will be held, by others that infringe upon the Patent Rights; (e) whether the Patent Rights and or any products to be produced thereunder will infringe on any other patents now held or that may be held by others; and (f) that Proteonomix has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to adequately conduct the necessary due diligence on the Patent Applications and the Patent Rights, and hereby accept all risks inherent thereto.
5. Patent Prosecution, Maintenance and Infringement.
a)
Patent Prosecution. Proteonomix shall pay for (i) all costs associated with prosecuting the Patent Applications from and after the date of this Agreement, to the extent such costs are reasonable and necessary to obtain such Patent Rights, and the Assignors shall cooperate to the fullest extent necessary if such prosecution is undertaken; (ii) all costs and expenses incurred in maintaining the Patent rights; and (iii) the costs of filing, prosecuting and maintaining foreign counterpart applications to the pending Patent Applications.
b)
Patent Attorneys. Preparation and maintenance of the Patent Applications and the Patent Rights shall be undertaken by Proteonomix at its costs and shall be performed by qualified and experienced patent attorneys mutually agreed upon by Proteonomix and the Assignor. Due diligence and care shall be used in preparing, filing, prosecuting and maintaining such applications on patentable subject matter. The Assignor and Proteonomix shall have the right to review and approve any and all patent related documents.
c)
Improvements. Proteonomix shall pay all future costs of preparation, filing, prosecuting and maintaining the Patent Applications and Patent Rights, as well as all patentable improvements made by Proteonomix in connection with the Patent Rights, and shall own outright any such improvements.
d)
Infringement. Proteonomix, at its expense, shall enforce the Patent Rights against infringement by third parties. Proteonomix shall retain recovery, if any, from such enforcement. In any infringement suit or dispute, the Parties shall cooperate fully with each other. At the request and expense of the Party bringing suit, the other Parties will permit access to all relevant personnel, records, papers, information, samples, specimens, etc.
6. Indemnification.
a)
Proteonomix shall indemnify, hold harmless and defend the Assignors from and against any and all allegations, claims, demands or causes of action whatsoever, including without limitation those arising on account of any injury, death or illness of persons, damage to property or improper business practices (the “Actions”) caused by, arising out of, or resulting from the exercise of the rights assigned to Proteonomix hereunder, unless and except to the extent that any Action is caused by a breach of any representation or warranty made herein by MC or JC (or by the Assignors, together).
b)
The Assignors shall indemnify, hold harmless and defend Proteonomix, its officers, directors, employees and agents from and against any and all Actions caused by, arising out of, or resulting from a breach of any representation or warranty herein made by the Assignors, or either of them.
c)
In no event shall any Party be liable for any indirect, special, consequential or punitive damages (including, without limitation, damages for loss of profits or other economic loss, or for injury to persons or to property) arising out of or in connection with this Agreement of the subject matter hereof.
7. Marking of Patent Rights. Proteonomix shall affix ‘patent pending’ and patent notices to all products produced from the technologies underlying the Patent Applications or the Patent Rights prior to any sale, in accordance with applicable patent laws. Each and every product produced pursuant to the Patent Applications or the Patent rights shall have either the words “PATENT PENDING” or “Patent Number followed by the patent application number or patent number conspicuously marked on each product offered for sale pursuant to the Patent Rights or Patent Applications.
Page 2 of 5
8. Rights Upon Granting of Patent(s). The Assignors hereby acknowledge that upon the granting of either or both of the pending patent applications, all rights, title and interest to such granted patent shall belong to Proteonomix, subject to any permissible assignment by Proteonomix.
9. Permissable Assignment By Proteonomix. Proteonomix may assign this Agreement to Proteoderm, upon Proteoderm’s assumption of all of the terms hereof.
10. Insurance. Beginning at the time when any Licensed Product is being produced, distributed or sold (including for the purpose of obtaining regulatory approvals) by Proteonomix, and continuing for the term of this Agreement, and for not less than two (2) years thereafter, Proteonomix shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than $2,000,000 per incident and $2,000,000 annual aggregate. Proteonomix shall use reasonable efforts to have the Assignors, named as additional insureds. The minimum amounts of insurance coverage required shall not be construed to create a limit of Proteonomix liability with respect to its indemnification under this Agreement. Proteonomix shall provide Assignors with written evidence of such insurance upon Assignor's request, and shall provide Assignor with written notice prior to the cancellation, non-renewal or material change in such insurance.
11.
Term and Termination
A.
Term. The term of this Agreement shall commence on the date of this Agreement and shall continue indefinitely unless if termination pursuant to “B” below
B.
Termination by the Assignors. Assignors may, at their option, terminate this agreement, upon written notice to Proteonomix if Proteonomix becomes bankrupt or insolvent, files a petition of bankruptcy, or a petition or answer seeking reorganization, readjustment, liquidation or rearrangement of its business or affairs under any law or governmental regulation relating to bankruptcy or insolvency, and/or if Proteonomix business is placed in the hands of a receiver, assignee, or trustee, whether by voluntary act of Proteonomix or otherwise;
8. Miscellaneous
a.
Confidential Information. Confidential information, whether in oral or written form, provided to one Party by the other (i) be received in strict confidence, (ii) be used only for the purposes of this Agreement, and (iii) not be disclosed by the recipient party, its agents or employees without the prior written consent of the other party, except to the extent that the recipient party can establish competent written proof that such information: (a) was in the public domain at the time of disclosure; (b) later became part of the public domain through no act or omission of the recipient party, it’s employees, agents, successors or assigns; (c) was lawfully disclosed to the recipient by a third party having the right to disclose it; or (d) is required by law or regulation to be disclosed. Each Party’s obligation of confidence hereunder shall be fulfilled by using at least the same degree of care with the other Party’s confidential information as it uses to protect its own confidential information. This obligation shall exist while this Agreement is in force and for a period of 2 years thereafter.
b,
Entire Agreement/Amendment. This Agreement constitutes the complete and entire agreement of the parties with respect to the subject matter hereof and supersedes any and all prior negotiations, written or oral agreements, understandings or negotiations concerning the subject matter hereof. This Agreement, including this provision, may not be amended, altered or supplemented without a written instrument signed by duly authorized representatives of both parties.
c.
Governing law . This Agreement shall be governed in accordance with the substantive laws of the State of New York, without regard to its conflicts of laws provisions.
d.
Compliance with Law. The Parties shall comply with all applicable federal, state and local laws and regulations in connection with its activities pursuant to this Agreement.
e.
Severability. If any part, term or provision of this Agreement shall be held to be invalid, illegal or unenforceable, such invalidity or unenforceability shall not invalidate or render unenforceable the
Page 3 of 5
entire agreement, but rather the entire agreement shall be construed as if not containing the particular invalid or unenforceable provision or provisions, and the rights and obligations of the parties shall be construed and enforced accordingly.
f.
Waiver. Failure of any party to enforce a right under this Agreement will not act as a waiver of that right or the ability to later assert that right relative to the particular situation involved.
g.
Notices. Any notice given by one Party to another pursuant to this Agreement shall be deemed to be given if personally served, mailed with a return or delivery receipt by US Postal Service or by recognized overnight carrier upon delivery at the address provided in the preamble to this Agreement as such address may be changed by a Party in writing to the other Parties
h.
Headings. Headings are included herein for convenience only and shall not be used to construe this Agreement.
i.
Multiple Counterparts. This Agreement may be executed in counterparts, all of which taken together shall constitute one single Agreement between the Parties.
j.
Corporate Authority. Proteonomix and Proteoderm hereby acknowledge that each has the corporate authority to enter into this Agreement.
IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written.
PROTEONOMIX, INC.
By: /s/ Joel Pensley
Joel Pensley, Secretary
PROTEODERM, INC.
/s/ Jacob Cohen
By /s/ Joel Pensley
Joel Pensley, Secretary
Page 4 of 5
PROTEONOMIX, INC ASSIGNMENT TO PROTEODERM, INC.
Proteonomix hereby, as of the date first above written, irrevocably assigns all of the rights, title and interest in and to the Patent Applications and the Patent rights, including all related discoveries, inventions and intellectual property, to Proteoderm, in consideration of prosecuting the Patent Applications and producing and marketing products using ingredients derived therefrom. The Subsidiary hereby restates all of the representations and warranties herein made by Proteonomix as if more fully set forth by Proteoderm herein, and assumes all of the rights, and each and every one of the obligations, herein granted to or incurred by Proteonomix.
IN WITNESS WHEREOF, the Parties have executed this Agreement as of the July 1, 2009.
PROTEONOMIX, INC.
By: /s/Michael Cohen
Michael Cohen, President
PROTEODERM, INC.
By: /s/ Joel Pensley
Joel Pensley, Secretary
The undersigned agree to the above agreement.
/s/ Michael Cohen
Michael Cohen, Assignor
/s/ Jacob Cohen
Jacob Cohen, Assignor
Page 5 of 5
| This ‘10-12G’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/4/09 | None on these Dates | ||
| 7/1/09 | ||||
| 12/19/06 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/21/10 SEC UPLOAD¶ 10/06/17 1:20K Proteonomix, Inc. 4/12/10 SEC UPLOAD¶ 10/06/17 1:43K Proteonomix, Inc. 3/04/10 SEC UPLOAD¶ 10/06/17 1:47K Proteonomix, Inc. 2/22/10 SEC UPLOAD¶ 10/06/17 1:44K Proteonomix, Inc. 1/25/10 SEC UPLOAD¶ 10/06/17 1:52K Proteonomix, Inc. 12/22/09 SEC UPLOAD¶ 10/06/17 1:80K Proteonomix, Inc. 11/06/09 SEC UPLOAD¶ 10/06/17 1:88K Proteonomix, Inc. 8/31/09 SEC UPLOAD¶ 10/06/17 1:231K Proteonomix, Inc. |